BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 23470576)

  • 1. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D; Hölscher AH; Dietlein M; Bollschweiler E; Baldus SE; Mönig SP; Metzger R; Schicha H; Schmidt M
    Ann Surg; 2009 Dec; 250(6):888-94. PubMed ID: 19953708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of
    Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
    J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma.
    Higuchi I; Yasuda T; Yano M; Doki Y; Miyata H; Tatsumi M; Fukunaga H; Takiguchi S; Fujiwara Y; Hatazawa J; Monden M
    J Thorac Cardiovasc Surg; 2008 Jul; 136(1):205-12, 212.e1-3. PubMed ID: 18603077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of surgical resection in complete responders on FDG-PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.
    Jeong Y; Kim JH; Kim SB; Yoon DH; Park SI; Kim YH; Kim HR; Jung HY; Lee GH; Ryu JS
    J Surg Oncol; 2014 Apr; 109(5):472-7. PubMed ID: 24301552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H; Yamasaki M; Takahashi T; Murakami K; Tanaka K; Yukinori K; Nakajima K; Takiguchi S; Morii E; Hatazawa J; Mori M; Doki Y
    Ann Surg Oncol; 2014 Feb; 21(2):575-82. PubMed ID: 24201746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Significance of (18)F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET)-Positive Lymph Nodes Following Neoadjuvant Chemotherapy and Surgery for Resectable Thoracic Esophageal Squamous Cell Carcinoma.
    Yasuda T; Yano M; Miyata H; Yamasaki M; Takiguchi S; Fujiwara Y; Doki Y
    Ann Surg Oncol; 2015 Aug; 22(8):2599-607. PubMed ID: 25524011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
    Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
    J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG PET using SUV
    Huang YC; Lu HI; Huang SC; Hsu CC; Chiu NT; Wang YM; Chiu YC; Li SH
    BMC Med Imaging; 2017 Jan; 17(1):1. PubMed ID: 28056868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
    Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.